IE40794L - Influenza vaccine. - Google Patents

Influenza vaccine.

Info

Publication number
IE40794L
IE40794L IE750059A IE5975A IE40794L IE 40794 L IE40794 L IE 40794L IE 750059 A IE750059 A IE 750059A IE 5975 A IE5975 A IE 5975A IE 40794 L IE40794 L IE 40794L
Authority
IE
Ireland
Prior art keywords
influenza
components
virus
type
cationic detergent
Prior art date
Application number
IE750059A
Other versions
IE40794B1 (en
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of IE40794L publication Critical patent/IE40794L/en
Publication of IE40794B1 publication Critical patent/IE40794B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

1498261 Influenza vaccines SANDOZ Ltd 13 Jan 1975 [14 Jan 1974] 1290/75 Heading A5B The haemagglutinin and neuramuridase components are isolated from influenza virus by treating the virus in an aqueous medium with a cationic detergent to selectively solubilise such components, and separating the resulting solubilised such components from residual sub-viral particles. The virus concentrate may have a pH of from 6.5 to 8.5 and may inactivated with formaldehyde prior to the addition of the cationic detergent. After addition of the cationic detergent, the resulting mixture is preferably allowed to stand for 30 minutes to 16 hours at 4‹C to 37‹C. Influenza vaccines comprise a mixture of the haemagglutinin and neuramuridase components of an influenza virus, in the substantial absence of other components of the influenza viral particle in association with -an inertliquid diluent such as physiological saline optionally phosphate buffered. The vaccine may additionally comprise a preserving or inactivating agent such as formaldehyde and/or an immunological adjuvant such as aluminium hydroxide or aluminium phosphate. The influenza virus may be an influenza Type A, A 1 , A 2 or B virus, strain A2/Aichi/68, MRC-2 (recombination of Type A2/England/42/72), MRC-11 (recombination of Type A2/Port Chalmers/73), A/Pasteur/30C (Mutagrip), or B/Mass/67. [GB1498261A]
IE59/75A 1974-01-14 1975-01-13 Influenza vaccines IE40794B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH44774A CH589453A5 (en) 1974-01-14 1974-01-14

Publications (2)

Publication Number Publication Date
IE40794L true IE40794L (en) 1975-07-14
IE40794B1 IE40794B1 (en) 1979-08-15

Family

ID=4187233

Family Applications (1)

Application Number Title Priority Date Filing Date
IE59/75A IE40794B1 (en) 1974-01-14 1975-01-13 Influenza vaccines

Country Status (27)

Country Link
JP (2) JPS58407B2 (en)
AT (1) AT345449B (en)
AU (1) AU500250B2 (en)
BE (1) BE824372A (en)
CA (1) CA1049406A (en)
CH (1) CH589453A5 (en)
CS (1) CS191254B2 (en)
DD (1) DD116239A5 (en)
DE (1) DE2500785B2 (en)
DK (1) DK140003B (en)
ES (1) ES433759A1 (en)
FI (1) FI54053C (en)
FR (1) FR2257305B1 (en)
GB (1) GB1498261A (en)
HK (1) HK56380A (en)
HU (1) HU173920B (en)
IE (1) IE40794B1 (en)
IL (1) IL46426A (en)
MY (1) MY8100204A (en)
NL (1) NL166622C (en)
NO (1) NO143128C (en)
PH (1) PH14458A (en)
PL (1) PL93689B1 (en)
SE (1) SE427238B (en)
SU (1) SU616997A3 (en)
YU (1) YU41289B (en)
ZA (1) ZA75259B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2829089A1 (en) * 1977-07-13 1979-02-01 Sandoz Ag SUBUNIT VACCINE
JPH0688911B2 (en) * 1985-06-06 1994-11-09 国立予防衛生研究所長 Influenza vaccine and method for producing the same
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
EP0919243A1 (en) 1997-11-25 1999-06-02 Duphar International Research B.V Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
DE19938767C2 (en) * 1999-08-16 2002-10-24 Tad Pharma Gmbh subunit vaccines
NZ567817A (en) * 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
AU2008293513B2 (en) * 2007-08-28 2013-11-21 Nanotherapeutics, Inc. Method for producing viral vaccines
EP3068791B1 (en) 2013-11-15 2020-07-29 Novartis AG Removal of residual cell culture impurities

Also Published As

Publication number Publication date
SE427238B (en) 1983-03-21
DK140003B (en) 1979-06-05
FR2257305A1 (en) 1975-08-08
YU41289B (en) 1987-02-28
HK56380A (en) 1980-10-16
JPS58407B2 (en) 1983-01-06
NL166622C (en) 1981-09-15
FR2257305B1 (en) 1982-03-19
ES433759A1 (en) 1977-02-16
NO143128B (en) 1980-09-15
BE824372A (en) 1975-07-14
AU7730575A (en) 1976-07-15
CS191254B2 (en) 1979-06-29
MY8100204A (en) 1981-12-31
YU5875A (en) 1984-04-30
DE2500785A1 (en) 1975-07-31
HU173920B (en) 1979-09-28
GB1498261A (en) 1978-01-18
DK140003C (en) 1979-10-29
PH14458A (en) 1981-07-29
FI750014A (en) 1975-07-15
DE2500785B2 (en) 1980-01-03
SU616997A3 (en) 1978-07-25
FI54053C (en) 1978-10-10
NL166622B (en) 1981-04-15
SE7500130L (en) 1975-07-15
DD116239A5 (en) 1975-11-12
JPS56127319A (en) 1981-10-06
PL93689B1 (en) 1977-06-30
NO750031L (en) 1975-08-11
IL46426A (en) 1978-01-31
DE2500785C3 (en) 1980-09-11
JPS6035326B2 (en) 1985-08-14
CH589453A5 (en) 1977-07-15
AT345449B (en) 1978-09-11
AU500250B2 (en) 1979-05-17
IL46426A0 (en) 1975-04-25
NO143128C (en) 1980-12-29
ZA75259B (en) 1976-08-25
IE40794B1 (en) 1979-08-15
DK1475A (en) 1975-09-01
FI54053B (en) 1978-06-30
CA1049406A (en) 1979-02-27
NL7500301A (en) 1975-07-16
ATA21475A (en) 1978-01-15
JPS50100224A (en) 1975-08-08

Similar Documents

Publication Publication Date Title
CA2121241A1 (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
IE40794B1 (en) Influenza vaccines
KR850001700A (en) Method for preparing Herpes Simplex Virus Subuait Vaccine
Lahelle et al. Hemagglutination with the GDVII strain of mouse encephalomyelitis virus
US3674864A (en) Process for stabilizing preparations of interfering viruses
Kurrle et al. Influenza virus‐specific T cell‐mediated cytotoxicity: integration of the virus antigen into the target cell membrane is essential for target cell formation
Bang Filamentous forms of Newcastle virus
GB1183506A (en) New vaccines for combating influenza and the preparation thereof
IE781880L (en) Immunogenic herpes virus subunit
Russell et al. Cell cooperation in antibody responses to influenza virus. I. Priming of helper T cells by internal components of the virion
ES8203225A1 (en) Process for isolating viral glycoproteic antigens, and its use in the preparation of vaccines.
ES471615A1 (en) Glycoproteins from paramyxovirus and vaccines therefrom
ES432385A1 (en) Influenza vaccines
EP1636352B1 (en) Improvements in virus production
IE40180L (en) Influenza virus vaccines.
Russell et al. Mumps Viral Cytolysin: I. Action on Human Epithelial Cells in Tissue Culture
AU5573196A (en) A pluripotent vaccine against enveloped viruses
Manischewitz et al. The effect of mycoplasmas on replication and plaquing ability of Herpes simplex virus
GB660109A (en) Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine
Laver et al. Preparation and immunogenicity of a purified influenza virus haemagglutinin and neuraminidase subunit vaccine
GB2038179A (en) Meningo-encephalitis virus vaccines
JP2841592B2 (en) Virus particle disruption method
Danes et al. Study of the possibility of preparing a vaccine against tick-borne encephalitis, using tissue culture methods. II. The inactivation by formaldehyde of the tickborne encephalitis virus in liquids prepared from tissue cultures. Immunogenic properties
GB1434181A (en) Vaccine for the prevention and treatment of vascular conditions
GB777018A (en) Poliomyelitis vaccine products and methods for preparing the same